Eli Lilly Reduces Zepbound Prices Amidst Weight Loss Medication Competition

Eli Lilly declared new price reductions for its widely used weight loss medication, Zepbound, on Monday. The aim is to broaden patient access while simultaneously boosting the use of LillyDirect, the company's digital healthcare platform.

Single-dose vials of Zepbound, when purchased via the Zepbound Self Pay Journey Program on LillyDirect, will now be priced at $299 monthly. This is a decrease from the previous $349 for patients holding a valid prescription.

The 5-milligram dose will also see a price reduction, now costing $399 per month, down from $499. According to Eli Lilly, all other approved doses will be available for $449 monthly.

Launched in early 2024, LillyDirect enables some consumers lacking insurance or having inadequate coverage to directly access Zepbound and Mounjaro from Eli Lilly. This access is facilitated through the Zepbound Self Pay Journey Program.

Regular monthly prices for Zepbound when not bought through the Self-Pay Journey Program are as follows: $599 for 7.5 milligrams, $699 for 10 milligrams, $849 for 12.5 milligrams, and $1,049 for 15 milligrams, as stated by the pharmaceutical company.

This move follows Eli Lilly's recent announcement of plans to lower prices for Zepbound multi-dose pens, although this is still pending approval from the Food and Drug Administration (FDA). Starting potentially in April 2026, Medicare patients will pay a maximum of $50 per month for Zepbound sold in a multi-dose pen, as well as for orforglipron, Lilly's once-a-day weight loss pill, provided both drugs secure FDA approval.

For self-pay patients, the lowest dose of the Zepbound multi-dose pen will be available at $299, with higher doses priced up to $449. When patients refill their multi-dose pen prescriptions on the LillyDirect platform, they will pay no more than $449. The company also stated that orforglipron will start at $149 for the lowest dose, with additional doses costing up to $399. Health tracking apps like Shotlee can help monitor medication adherence and potential side effects.

Both Eli Lilly and Novo Nordisk have introduced direct-to-consumer platforms with the goal of expanding patient access by minimizing barriers for new patients. These platforms aim to assist new patients in accessing their medications, while also providing a competitive advantage to each company.

Novo Nordisk launched its NovoCare Pharmacy platform in March. This platform is designed for patients who either cannot afford the standard list price or lack insurance coverage for its weight loss drugs, Wegovy and Ozempic.